Hangzhou Alltest Biotech Co (688606) Fair Value & Analysis
Healthcare · CN · Market cap 3.7B CNY
Fair value as of: Jul 12, 2026
From 15 valuation models · updated 29 days ago
Share price +10.1% over the past month.
A solid business, screening 31% undervalued on our models.
What matters now
- Solid quality (60/100) at a price below fair value, the discount is the argument here, not the business quality.
- Our model range runs from ¥45.43 (bear) to ¥75.71 (bull), base ¥60.57. The closer the price sits to the lower half, the larger the margin of safety.
- Quality 60/100 (solid quality) with medium evidence: read the verdict with care.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 12, 2026.
How to read this chart
60‑month range ¥41.00 – ¥120.93 · fair‑value band ¥45.43 – ¥75.71 · the ¥46.39 price screens below the ¥60.57 fair value. Dashed = 300-day average. As of Jul 12, 2026.
Analysis
Hangzhou Alltest Biotech Co (688606) currently trades at ¥46.39, while our model-based Fair Value estimate is ¥60.57, implying the stock looks roughly 30.6% undervalued today. The Quality Score stands at 60/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium), always confirm before acting.
Over the trailing twelve months, Hangzhou Alltest Biotech Co generated revenue of 892M CNY at a net margin of 20.0%. Revenue declined 6.3% year over year. It earns a return on equity of 4.6%. The balance sheet holds a net cash position of 919M CNY. Fundamentals as of Jul 12, 2026
Our scenario range runs from ¥45.43 (bear case) to ¥75.71 (bull case); at ¥46.39, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 38% below its 52-week high, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -43% fair-value upside, at 31%, 688606 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 15 models by family
Widest divergence: Growth Earnings (¥90.45) versus DCF Models (¥30.61). Highest evidence: Residual Income (76).
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 12, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 59 · Market factors (momentum, volatility) 29
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Hangzhou Alltest Biotech Co., Ltd. engages in the research, development, production, and sale of in vitro diagnostic reagents in China and internationally. The company offers rapid diagnostic reagents, including drug and drug abuse, infectious disease, women's health, tumor marker, and cardiac marker testing products.
Full company description
Hangzhou Alltest Biotech Co., Ltd. engages in the research, development, production, and sale of in vitro diagnostic reagents in China and internationally. The company offers rapid diagnostic reagents, including drug and drug abuse, infectious disease, women's health, tumor marker, and cardiac marker testing products. Its products include COVID-19 antigen and antibody tests; veterinary tests; fluorescence immunoassay tests and analyzers; urine analysis solutions, biochemistry reagents, VTM, blood glucose monitoring systems, and HB hemoglobin test meters. In addition, the company offers SARS-COV-2 RT-qPCR assays, virus specimen stabilizers, and viral DNA/RNA extraction kits; and other test products. Its products are used in clinical testing, on-site testing, personal health management, and other fields. Hangzhou Alltest Biotech Co., Ltd. was founded in 2009 and is based in Hangzhou, China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Hangzhou Alltest Biotech Co reported revenue of ¥911M in FY2025 versus ¥1.9B in FY2021, a compound −16.5%/yr. Reported net income was ¥218M in FY2025, compounding −26.9%/yr from FY2021.
Watch 688606: get an alert when its fair value changes →
Peer Group
Medical Instruments & Supplies · 203 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Instruments & Supplies median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate (as of Jul 12, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Intuitive Surgical, Inc ISRG | $402.33 | $150.04 | -63% |
| EssilorLuxottica Société anonyme 1EL | €172.45 | €68.55 | -60% |
| Medline Inc MDLN | $41.11 | $30.15 | -27% |
| Becton, Dickinson and Company BDX | $150.65 | $103.53 | -31% |
| Alcon Inc ALC | $70.26 | $39.78 | -43% |
| ResMed Inc RMD | $203.87 | $187.89 | -8% |
| West Pharmaceutical Services, Inc WST | $353.71 | $143.97 | -59% |
| Straumann Holding STMN | CHF 106.00 | CHF 47.31 | -55% |
| Sartorius Stedim Biotech S.A DIM | €188.50 | €51.16 | -73% |
| Coloplast A/S COLOB | kr 414.00 | kr 382.22 | -8% |
Compare Hangzhou Alltest Biotech Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Hangzhou Alltest Biotech Co (688606) overvalued or undervalued?
What is the fair value of 688606?
What is the quality score of 688606?
What is the revenue of Hangzhou Alltest Biotech Co (688606)?
What is the net profit margin of 688606?
Does Hangzhou Alltest Biotech Co pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Hangzhou Alltest Biotech Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.